2 Bridge

Executive Summary

2 Bridge is a Belgian private pre-clinical biotech company founded in 2020 by four experienced drug developers with complementary expertise. The company leverages artificial intelligence and machine learning to enhance drug delivery, aiming to improve efficacy and reduce side effects. Growing from a small core team to over thirty highly educated scientists, healthcare industry leaders, and entrepreneurs, 2 Bridge focuses on developing novel delivery technologies for therapeutics. Though still in the pre-clinical stage with no disclosed pipeline or funding, the company's AI-driven approach and experienced team position it to address key challenges in drug delivery. Initial efforts appear centered on leveraging computational models to optimize formulation and targeting, potentially applicable across multiple therapeutic areas. The company's Leuven location benefits from a strong European biotech ecosystem. Given its early stage, 2 Bridge's near-term value will depend on advancing its platform toward clinical validation and securing partnerships or financing.

Upcoming Catalysts (preview)

• Q2 2026Completion of Key Preclinical Proof-of-Concept Studies60% success
• Q4 2026Series A Financing Round50% success
• H1 2027Strategic Partnership or Licensing Deal with a Pharma Company30% success